Professor Heather Payne is a Consultant Clinical Oncologist, specialising in urological and prostate cancer at University College London Hospitals NHS Trust and she also sees patients privately, including at The Harley Street Clinic and The Prostate Centre.

Professor Payne trained at St Mary’s Hospital and after qualifying, spent time in general medicine in London and Haiti.

On her returned to London, she trained as a Clinical Oncologist, and also developed an interest in urological oncology.

In addition to her clinical work, she is also actively involved in research, and she has pioneered a program of high-dose rate brachytherapy for prostate cancer. Current research interests include hormone therapy, sensitisation of hormones and radiotherapy, predictive indices for bowel toxicity with radiotherapy, proton beam therapy for prostate cancer, chemotherapy and assisting men with decision making and prostate cancer.

Professor Payne is principal investigator in a number of international and national studies and has been published in peer-reviewed journals. She is Chair of the British Uro-oncology Group and Oncology Lead for the National Prostate Cancer Audit. She also serves on the Prostate Cancer Advisory Group for the UK.

Diseases, Medical Tests and Treatments

• External Beam Radiotherapy
• Intensity Modulated Radiotherapy/Rapid Arc
• Low Does Brachytherapy
• Hormone Treatment
• Prostate Cancer
• Novel Hormone Therapy
• External beam radiotherapy
• Chemotherapy
• Brachytherapy
• 
  

Dr Daniel Krell is a Consultant Oncologist, specialising in gastro-oesophageal, colorectal, pancreatic, liver and bile duct cancers and neuroendocrine tumours. He is experienced in using chemotherapy, targeted therapy and immunotherapy. Dr Krell also manages patients with cancer of unknown primary and is the clinical lead for this. He works as a member of the multidisciplinary team for gastro-oesophageal and hepatobiliary cancer at the Royal Free Trust. He is also the clinical lead for Neuroendocrine tumour oncology at The Royal Free Hospital.

He undertook oncology training at University College and the Royal Free Hospitals in London. In addition to his primary medical degree, he also gained a Bachelor’s degree in immunology and microbiology, in addition to a DPhil in Clinical Medicine at the University of Oxford’s Wellcome Trust Centre for Human Genetics and was funded by Cancer Research UK and HCA. His research involved the design of models to investigate the role that genetic mutations in genes controlling cellular metabolism play in the development of cancer. This may help identify new therapeutic targets in this area. Dr Krell continues to be involved in clinical research and trials aimed at identifying new cancer therapies, focused on gastrointestinal, hepatobiliary and neuroendocrine tumours. He has published a number of peer-reviewed papers and presented at national and international conferences.

Diseases, Medical Tests and Treatments

• Chemotherapy
• Immunotherapy
• Biological Therapy
• Genetic Testing
• Liver Cancer
• Biliary Cancer
• Bowel Cancer
• Colorectal Cancer
• Oesophageal Cancer
• Pancreatic Cancer

Dr Thomas Newsom-Davis a Consultant Medical Oncologist at Chelsea and Westminster Hospital. He specialises in thoracic malignancies, especially lung cancer and mesothelioma. In 2015, he was awarded the Macmillan Innovation Excellence Award.

Training

Dr Newsom-Davis completed his training at University College and Middlesex School of Medicine, London, in 1998, including First Class honours for his BSc. He went on specialise in medical oncology at Charing Cross and Hammersmith Hospitals and completed a PhD in tumour immunology. He was appointed to Chelsea & Westminster Hospital in 2010.

Current Roles

Dr Newsom-Davis leads the lung cancer service for Chelsea & Westminster Hospital, and is Vice Chair of the British Thoracic Oncology Group (BTOG) Steering Committee, an organistion which supports and educates thoracic oncology profressionals across the United Kingdom. Dr Newsom-Davis is Chair of the Harley Street Clinic lung cancer multidisciplinary team (MDT), and Chair of the HCA Healthcare UK Thoracic Oncology Board.

Research

Dr Newsom-Davis has an active clinical trial portfolio, and has presented his work at National and International meetings. He has been an invited lecturer for organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

• Immunotherapy, Targeted Therapy, Chemotherapy
• Lung Cancer
• Mesothelioma

Dr Mulholland is a medical Oncologist who exclusively treats brain cancer at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre.He is also an honorary senior lecturer at UCL and a training programme director. 

His doctoral research was in genomic profiling in brain cancer at Cancer Research UK - this has led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally. 

He is a clinical lead in a European Consortium called Datrix, a multidisciplinary European collaboration to advance next-generation targeted hyperthermic cancer treatment for glioblastoma.

Diseases, Medical Tests and Treatments

• Cancer prevention and screening 
• Chemotherapy 
• Brain cancer 
• Neuro-endocrine tumours 
• Central nervous system cancer 
• Novel agents 

Dr Katharine Pigott graduated from the University of London in 1995 having trained at The Middlesex Hospital. She specialised in Clinical Oncology training at The Westminster Hospital and Charing Cross Hospital. She also spent two years working as a research fellow at Mount Vernon Hospital and the Gray Laboratory running clinical trials in hyper fractionation and undertaking an MD in measuring late radiation damage. She took up a consultant post at The Royal Free in 1996 and worked there for twenty years specialising in the management and treatment of urological cancers and breast cancer.

During her time at The Royal Free, she was head of the Radiotherapy Department and Chair of The London Cancer Radiotherapy Expert Reference Group. Her clinical interests are research in breast and prostate cancer particularly in new radiotherapy technique and clinical trials. She was the radiotherapy lead for the TARGIT Academy at The Royal Free which taught intraoperative radiotherapy (IORT) to centres throughout the world and participated in the TARGIT trials.

She has published peer-review papers and co-edited books on the urological condition and intraoperative radiotherapy.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

• Decision making for localised prostate cancer
• Management of localised and metastatic prostate cancer
• Management of breast cancer
• External beam radiotherapy
• Cyberknife
• Rapid Arc/ Intensity-modulated radiotherapy
• IORT intra-operative radiotherapy
• Hormone treatment
• Chemotherapy Radioisotope treatment
• Decision making for localised prostate cancer
• Management of localised and metastatic prostate cancer
• Management of breast cancer
• External beam radiotherapy
• Cyberknife
• Rapid Arc/ Intensity-modulated radiotherapy
• IORT intra-operative radiotherapy
• Hormone treatment
• Chemotherapy Radioisotope treatment

Dr Sarah Harris has been a Consultant Clinical Oncologist working at Guy’s and St Thomas’ NHS Trust for over 20 years. She now only sees patients privately at a range of private centres across London as well as by remote video consultation . Her areas of interests include breast cancer, prostate cancer and urological cancer, and she treats these conditions using radiotherapy and chemotherapy in central London and the south east of England.

She has extensive clinical experience in the management of breast cancer using radiotherapy and drug treatments. She has a specialist interest in technical radiotherapy due to its maximal benefits and reduced side effects. In particular she uses heart sparing radiotherapy techniques for left-sided breast radiotherapy. Furthermore, she regularly uses stereotactic radiotherapy for the treatment of localised recurrent cancers using the latest radiotherapy technologies, cyberknife and SABR. For the treatment of prostate cancer, she can perform external radiotherapy using modern IMRT and IGRT.

Along with her wealth of experience, she completed specialist training in proton beam radiotherapy at the University Of Pennsylvania in 2020. Dr Harris also holds many professional memberships, including the Royal College of Physicians and the Royal College of Radiologists.

In her leisure time , she is a keen golfer aspiring to a single figure handicap.

• Radiotherapy
• Chemotherapy
• CyberKnife therapy
• Stereotactic Ablative Radiotherapy (SABR)
• Proton beam radiotherapy

• Breast Cancer
• Prostate Cancer
• Urological Cancers

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Dr Stephen Morris is a consultant in Clinical Oncology at Guy's and St Thomas' Hospitals, specialising in the management of skin and urological cancers. He specialises in brachytherapy, external beam radiotherapy and chemotherapy for prostate cancer at Guys Hospital. He also leads the chemotherapy and radiotherapy service for cutaneous lymphoma at the St Johns Institute of dermatology at Guys.

Dr Morris completed his initial medical training at Guy's and St Thomas' medical school. Following this, he trained in clinical oncology at the Royal Marsden Hospital and the Guy's and St Thomas' Cancer Centre. At Guys he was involved in setting up the dynamic prostate brachytherapy service and since his appointment as a consultant, has continued to innovate in the field, working for ever-improving outcomes for patients.

In addition to his work in research and clinical trials, he has led the design and implementation of a new modern Total Skin Electron Beam technique for cutaneous lymphoma, IMRT and IGRT for prostate cancer and more recently has developed and implemented the use of the SpaceOAR and Auto Beam Hold intra fraction IGRT technique for prostate cancer. Dr Morris is also a keen teacher and involved in education as a tutor for clinical oncology.

• Prostate brachytherapy
• Radiotherapy
• Chemotherapy
• Clinical Trials

• Urological oncology 
• Dermatological oncology
• Cutaneous lymphoma and melanoma
• Prostate cancer

Professor Elinor Sawyer is a Consultant Clinical Oncologist with a specialist interest in the treatment of breast cancer. She is based at Guy’s & St Thomas’ Hospital but also performs private work and is Professor in Oncology at King’s College London.

She completed her clinical oncology training at University College London, Royal Free and St Thomas’ Hospitals. Following this, she obtained her PhD in molecular genetics of cancer at the London Research Institute. In 2005 she was appointed as a Consultant Oncologist at Guy’s & St Thomas’ Hospital.

As well as her clinical practice, Professor Sawyer is heavily involved in research and her work has been published in a number of peer reviewed journals. Her main areas of research include genetic predisposition to breast cancer, particularly lobular breast cancer and pre invasive cancer (DCIS and LCIS), and identification of biomarkers that predict progression of early breast cancer.

• Chemotherapy 
• Immunotherapy 

• Breast Cancer 

Professor Andrew Tutt is a Consultant Clinical Oncologist specialising in breast cancer. He is based at Guy’s Hospital Breast Unit but also performs private work and is a Professor of Oncology at King’s College London School of Medicine.

He qualified in medicine in 1990 and went on to complete his postgraduate training at a number of hospitals around the UK. After completing his clinical oncology training at the Royal Marsden Hospital London, he was awarded a Doctoral Research Training Fellowship at The Institute of Cancer Research, London, where he gained his PhD in cancer biology.

Professor Tutt is actively involved in clinical research and has published a number of breast cancer research papers. His main areas of research include the ‘triple negative’ and BRCA1 and BRCA2 associated breast cancers. He has led a number of international trials of drug therapies and research programmes in these areas.

He is often asked to speak at major European and North American Cancer Medicine conferences. He is a member of the St Gallen International Breast Cancer Consensus Panel that develops guidelines for the treatment of breast cancer. He is also part of a UK team that trial new techniques in breast radiotherapy.

• Biological Therapy 
• Chemotherapy 
• Radiotherapy 

• Breast Cancer